Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial-Reference-Cited by-同舟云学术

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Published:2013-07 Issue:8 Volume:14 Page:777-786
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wu Yi-Long,Lee Jin Soo,Thongprasert Sumitra,Yu Chong-Jen,Zhang Li,Ladrera Guia,Srimuninnimit Vichien,Sriuranpong Virote,Sandoval-Tan Jennifer,Zhu Yunzhong,Liao Meilin,Zhou Caicun,Pan Hongming,Lee Victor,Chen Yuh-Min,Sun Yan,Margono Benjamin,Fuerte Fatima,Chang Gee-Chen,Seetalarom Kasan,Wang Jie,Cheng Ashley,Syahruddin Elisna,Qian Xiaoping,Ho James,Kurnianda Johan,Liu Hsingjin Eugene,Jin Kate,Truman Matt,Bara Ilze,Mok Tony

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Optimizing first-line treatment options for patients with advanced NSCLC;Wakelee;Oncologist,2005

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans;2024-09-06

2. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR‐mutated NSCLC with high thrombospondin‐1 expression;Cancer Science;2024-06-28

3. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials;Expert Review of Anticancer Therapy;2024-06-03

4. CACA guidelines for holistic integrative management of lung cancer;Holistic Integrative Oncology;2024-03-08

5. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations;Current Treatment Options in Oncology;2023-12